# HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA

> **NCT02379520** · PHASE1 · COMPLETED · sponsor: **Baylor College of Medicine** · enrollment: 32 (estimated)

## Conditions studied

- Human Papillomavirus-Related Carcinoma
- Human Papillomavirus Positive Oropharyngeal Carcinoma
- Human Papillomavirus Positive Cervical Carcinoma
- Human Papillomavirus Positive Anal Carcinoma
- Human Papillomavirus Positive Vulvar Carcinoma
- Human Papillomavirus Positive Penile Carcinoma

## Interventions

- **GENETIC:** HPV Specific T Cells
- **DRUG:** Cytoxan
- **DRUG:** Fludarabine
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT02379520
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2026-01
- **Final completion:** 2026-01
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02379520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02379520, "HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02379520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*